Adjusted stage-specific HRs and excess HRs of death for patients with colon and rectal cancer, England, January 2010–March 2013
| Colon (n=38 070) | Rectum (n=22 631) | |||||||||||
| Overall survival | Overall survival | Net survival | Overall survival | Overall survival | Net survival | |||||||
| Cox modela | FPM with TVCsb | FPM with TVCsc | Cox modeld | FPM with TVCse | FPM with TVCsf | |||||||
| Adjusted HR | 95% CI | Adjusted HR | 95% CI | Adjusted EHR | 95% CI | Adjusted HR | 95% CI | Adjusted HR | 95% CI | Adjusted EHR | 95% CI | |
| Stage I | ||||||||||||
| SES 1 (affluent) | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
| 2 | 1.04 | 0.79 to 1.37 | 1.03 | 0.78 to 1.37 | 1.10 | 0.49 to 2.46 | 1.02 | 0.77 to 1.34 | 1.02 | 0.77 to 1.34 | 1.33 | 0.56 to 3.14 |
| 3 | 0.99 | 0.74 to 1.32 | 0.99 | 0.74 to 1.32 | 0.65 | 0.23 to 1.82 | 1.11 | 0.85 to 1.45 | 1.11 | 0.85 to 1.46 | 1.40 | 0.59 to 3.29 |
| 4 | 1.07 | 0.80 to 1.43 | 1.07 | 0.80 to 1.43 | 1.16 | 0.51 to 2.67 | 1.14 | 0.87 to 1.49 | 1.14 | 0.87 to 1.50 | 1.32 | 0.55 to 3.18 |
| 5 (deprived) | 1.18 | 0.88 to 1.59 | 1.20 | 0.89 to 1.60 | 1.56 | 0.71 to 3.44 | 1.44 | 1.09 to 1.90 | 1.45 | 1.10 to 1.91 | 2.00 | 0.86 to 4.66 |
| Stage II | ||||||||||||
| SES 1 | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
| 2 | 1.03 | 0.89 to 1.18 | 1.02 | 0.89 to 1.18 | 0.97 | 0.76 to 1.25 | 0.98 | 0.80 to 1.20 | 0.98 | 0.80 to 1.21 | 0.89 | 0.64 to 1.24 |
| 3 | 1.11 | 0.97 to 1.28 | 1.11 | 0.97 to 1.28 | 1.01 | 0.78 to 1.30 | 1.15 | 0.95 to 1.40 | 1.15 | 0.95 to 1.40 | 1.15 | 0.85 to 1.55 |
| 4 | 1.38 | 1.20 to 1.58 | 1.37 | 1.19 to 1.57 | 1.53 | 1.21 to 1.93 | 1.14 | 0.94 to 1.39 | 1.14 | 0.94 to 1.39 | 1.16 | 0.86 to 1.57 |
| 5 | 1.45 | 1.26 to 1.67 | 1.43 | 1.24 to 1.65 | 1.56 | 1.22 to 1.99 | 1.33 | 1.08 to 1.63 | 1.33 | 1.09 to 1.64 | 1.41 | 1.04 to 1.91 |
| Stage III | ||||||||||||
| SES 1 | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
| 2 | 1.16 | 1.05 to 1.29 | 1.17 | 1.05 to 1.29 | 1.16 | 1.02 to 1.32 | 0.98 | 0.85 to 1.13 | 0.98 | 0.84 to 1.13 | 0.96 | 0.80 to 1.16 |
| 3 | 1.11 | 0.99 to 1.23 | 1.11 | 1.00 to 1.23 | 1.06 | 0.93 to 1.22 | 1.07 | 0.93 to 1.24 | 1.07 | 0.93 to 1.24 | 1.04 | 0.86 to 1.25 |
| 4 | 1.19 | 1.07 to 1.32 | 1.20 | 1.08 to 1.33 | 1.13 | 0.98 to 1.29 | 1.11 | 0.96 to 1.28 | 1.11 | 0.96 to 1.28 | 1.10 | 0.91 to 1.32 |
| 5 | 1.33 | 1.19 to 1.48 | 1.33 | 1.19 to 1.49 | 1.29 | 1.12 to 1.48 | 1.08 | 0.93 to 1.25 | 1.08 | 0.93 to 1.25 | 1.04 | 0.85 to 1.26 |
| Stage IV | ||||||||||||
| SES 1 | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
| 2 | 0.96 | 0.90 to 1.04 | 0.97 | 0.90 to 1.04 | 0.96 | 0.89 to 1.04 | 0.95 | 0.85 to 1.05 | 0.95 | 0.85 to 1.05 | 0.95 | 0.85 to 1.06 |
| 3 | 1.00 | 0.93 to 1.07 | 1.00 | 0.93 to 1.07 | 0.98 | 0.91 to 1.06 | 1.00 | 0.90 to 1.11 | 1.00 | 0.90 to 1.11 | 0.99 | 0.89 to 1.11 |
| 4 | 1.04 | 0.96 to 1.12 | 1.04 | 0.97 to 1.12 | 1.03 | 0.95 to 1.11 | 0.96 | 0.87 to 1.07 | 0.97 | 0.87 to 1.08 | 0.94 | 0.84 to 1.05 |
| 5 | 0.99 | 0.92 to 1.08 | 0.99 | 0.92 to 1.08 | 0.96 | 0.89 to 1.05 | 1.15 | 1.03 to 1.28 | 1.14 | 1.03 to 1.27 | 1.09 | 0.97 to 1.22 |
Interaction between SES and stage is added for all models. Calculated for complete cases only.
Model a, b, c: adjusted for sex, age, site, tumour grade, emergency presentation, receipt of major resection, number of chronic and acute comorbidities.
Model d, e, f: adjusted for sex, age, year of diagnosis, site, tumour grade, emergency presentation, receipt of major resection, number of chronic and acute comorbidities.
EHR, excess HR; FPM, flexible parametric model; SES, socioeconomic status; TVC, time-varying covariate.